Personalized Support

Living with acute intermittent porphyria (AIP) can be challenging, but there is help available. Check out the resources below.

Personalized education and support for women with AIP receiving treatment with PANHEMATIN

Patient Advocacy Liason For Individuals Taking PANHEMATIN
Helga, Patient Advocacy Liaison (PAL)
Recordati Rare Diseases
Patient Support Services

The Patient Advocacy Liaison (PAL) program provides one-on-one support for patients and caregivers that may include*:

  • Providing education about acute intermittent porphyria (AIP) and how it can impact the body
  • Answering questions you might have about PANHEMATIN, such as questions about administration or how PANHEMATIN works
  • Helping you if issues arise accessing PANHEMATIN
  • Helping you to connect with resources regarding AIP
  • Helping you to create a personalized plan to prepare for AIP attacks
  • Providing PAL program services in Spanish, if requested.

*Information provided by the PAL program is for educational purposes only and is not intended to replace the care and advice of patients’ healthcare providers.

These services are provided at no additional cost to you by Recordati Rare Diseases (the maker of PANHEMATIN) to help you manage the PANHEMATIN therapy. For medical care, please contact your doctor or nearest urgent care provider.

To Get Started, Complete The Program Enrollment Opt-in Form:

COMPLETE THE OPT-IN FORM

The PAL will contact you upon receipt of the opt-in form.

Watch these videos to learn more about the PANHEMATIN PAL program:

Introducing the Patient Advocacy Liaison program for patients receiving treatment with PANHEMATIN

Meet Helga, a Patient Advocacy Liaison for patients receiving treatment with PANHEMATIN

How the Patient Advocacy Liaison program for patients receiving treatment with PANHEMATIN has helped individuals living with AIP

Additional Reimbursement and Financial Support Programs

Recordati Rare Diseases has a free support program for eligible people living with AIP. The support program can also help caregivers, doctors and medical staff, and others who have questions about PANHEMATIN insurance coverage and related issues. Contact the Recordati Rare Diseases Patient Support Program hotline for:

Contact The Recordati Rare Diseases Patient Support Program

Monday-Friday from 9 AM to 5 PM ET
Hotline: 866-209-7604 (toll-free)
Fax: 866-209-7599

Access and Reimbursement Support

  • Insurance verification - Help with confirming that your insurance company will cover PANHEMATIN, and help with understanding your insurance benefits.
  • Insurance counseling - Help with exploring other insurance options if you are uninsured or underinsured for PANHEMATIN.
  • Additional approvals for coverage - Help work with your doctor's office and insurance company if additional approvals are needed.
  • Insurance company education - Help with educating insurers about PANHEMATIN to speed up decisions about coverage and payment.

Financial Assistance

  • Copay assistance program - Help with your copay if you're an eligible patient who receives PANHEMATIN infusions in an outpatient care setting.
  • Patient Assistance Program (PAP) - Assistance with accessing PANHEMATIN if you are an eligible patient who doesn't have insurance or are underinsured.
  • Additional referrals - Help with referrals to outside assistance sources when available.

Online Resources

For more information about AIP, check out these educational and support resources.

The APF educates people with porphyrias, their families, and doctors; raises funds for research; and promotes better patient care.

VISIT SITE

NORD is a group of health organizations dedicated to helping people with rare “orphan” diseases.

VISIT SITE

The Porphyrias Consortium, part of the Rare Diseases Clinical Research Network, helps patients, families, and doctors through joint efforts to improve the diagnosis, treatment, and prevention of illness and disability caused by the porphyrias.

VISIT SITE

The UPA is committed to improving the quality of life of people with porphyria and focuses on advancing disease awareness, research, and therapies.

VISIT SITE

Important Safety Information